Saudi Arabia Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

Saudi Arabia Human Insulin Market was valued at USD 0.32 Billion in 2024 and is expected to reach USD 0.35 Billion by 2030 with a CAGR of 1.70%. during forecast period Human insulin is a peptide hormone that plays a crucial role in regulating blood sugar levels in the human body. It is produced by the beta cells of the pancreas, specifically in the Islets of Langerhans, and is essential for the uptake and utilization of glucose by the body's cells. Human insulin is a protein hormone composed of 51 amino acids organized into two chains: an A-chain with 21 amino acids and a B-chain with 30 amino acids. These two chains are held together by disulfide bonds. Human insulin is synthesized within the pancreas as a precursor molecule known as proinsulin. Proinsulin is later processed to produce the active insulin molecule. During this processing, a portion of the proinsulin molecule, called the C-peptide, is cleaved, and released into the bloodstream along with the active insulin.  The primary role of insulin is to regulate blood sugar (glucose) levels. It acts as a key that allows glucose to enter cells, where it can be used for energy production. When blood sugar levels rise, typically after eating, the pancreas releases insulin to facilitate the uptake of glucose into cells, thereby reducing blood sugar levels.

An aging population is more prone to diabetes, particularly Type II diabetes. As the demographic structure of the country changes, the market for insulin expands. Urbanization is associated with lifestyle changes that increase the risk of diabetes. Saudi Arabia's ongoing urbanization drives the need for diabetes management and insulin therapy. Greater awareness about the importance of early diabetes diagnosis and management encourages more people to seek medical care and insulin therapy. Advances in insulin delivery systems and monitoring technologies improve the convenience and effectiveness of insulin therapy, encouraging more people to use insulin. Expanding health insurance coverage and reimbursement policies for insulin and related supplies can reduce the financial burden on patients and promote insulin use. Healthcare providers' recommendations and prescriptions of insulin for diabetes management are a significant driver. The trust and advice of medical professional’s influence patient choices.

Key Market Drivers

Rising Prevalence of Diabetes

The rising prevalence of diabetes in Saudi Arabia is a fundamental and powerful force propelling the growth of the human insulin market. According to the International Diabetes Federation (IDF), approximately 18.7% of Saudi Arabia’s adult population between the ages of 20 and 79 is currently living with diabetes. This chronic health condition is not only increasing in incidence but also becoming a long-term public health concern, resulting in a steadily expanding demand for insulin therapy across the country. Saudi Arabia ranks among the top countries globally with high diabetes prevalence. The prevalence of Type 2 Diabetes Mellitus (T2DM) in Saudi Arabia has seen a sharp escalation from 8.5% in 1992 to 39.5% by 2022, reflecting the growing metabolic health crisis within the Kingdom. Notably, projections indicate that the 2022 diabetes prevalence could have been 10% lower had obesity rates declined, highlighting a direct correlation between the country’s rising obesity levels and the surge in T2DM cases. This growing diabetic population creates a direct and sustained demand for insulin products, particularly for Type 1 Diabetes patients who rely entirely on insulin for survival, and for many Type 2 patients whose condition progresses to the point of requiring insulin therapy. In Saudi Arabia, diabetes often presents at a younger age due to genetic predisposition, high obesity rates, and unhealthy lifestyle choices. When diabetes is diagnosed early, the treatment duration with insulin is extended, as patients live longer with the disease. This results in higher lifetime consumption of human insulin per patient, magnifying overall market demand.

Although Type 2 Diabetes is initially managed through oral medications and lifestyle modifications, many patients eventually require insulin to achieve adequate glycemic control. With the increasing number of Type 2 cases in the Kingdom, particularly among middle-aged and elderly populations, there is a notable shift toward insulin therapy as a second-line or adjunct treatment, further boosting market growth. The growing diabetes burden has led to intensified efforts by the government and private sector to enhance screening and diagnostic initiatives. This has resulted in higher detection rates, even in previously underserved rural areas. As more individuals are diagnosed earlier, they enter the healthcare system sooner, and many begin insulin therapy earlier in the disease course, thereby increasing market volume. Diabetes is a lifelong condition, and insulin is a repeat-purchase pharmaceutical product. Unlike short-term treatments, insulin use continues for the entire duration of a patient’s life once initiated. As the number of diabetic patients climbs, so does the cumulative and recurring demand for insulin, creating a stable revenue stream for manufacturers and distributors.

Aging Population and Lifestyle Changes

The dual impact of an aging population and widespread lifestyle changes is significantly accelerating the demand for human insulin in Saudi Arabia. These two interconnected factors are not only contributing to a higher incidence of diabetes but are also reshaping the nation’s healthcare needs, thereby driving robust growth in the insulin market. Saudi Arabia is witnessing a gradual but steady demographic shift, with an increasing proportion of its population entering the middle-aged and elderly brackets. The share of Saudi Arabia’s population aged 60 and above is projected to quadruple from 6.9% in 2020 to 25% by 2050, marking a substantial demographic shift toward an aging society. Older adults are biologically more susceptible to developing Type 2 Diabetes due to insulin resistance, slower metabolism, and age-related changes in pancreatic function. As this segment of the population expands, the prevalence of diabetes increases proportionately, leading to a corresponding surge in demand for insulin-based therapies.

Non-communicable diseases (NCDs) account for a dominant 73% of all deaths in Saudi Arabia, underscoring their critical impact on national health outcomes. Cardiovascular diseases lead to NCD-related mortality, followed by cancer and diabetes. The widespread prevalence of hypertension, diabetes, and obesity among adults further exacerbates this trend, placing sustained pressure on the healthcare system and driving increased demand for long-term therapeutic solutions, including human insulin for diabetes management. Saudi Arabia is experiencing intensifying urbanization, with over 80% of its population currently living in urban areas a figure projected to rise to 97.6% by 2030. This shift is not limited to major cities like Riyadh and Jeddah; it also includes rapid expansion in secondary urban centers, signaling broader lifestyle transformations. The urban concentration is closely linked to rising rates of sedentary behavior, poor dietary habits, and increased incidence of non-communicable diseases such as Type 2 Diabetes, thereby reinforcing sustained demand for insulin-based therapies across a geographically expanding market. These behavioral and environmental changes have contributed significantly to the rise in obesity and metabolic disorders, which are primary risk factors for the onset of Type 2 Diabetes. This has led to a younger demographic being affected, often at earlier ages, creating a broader and more diverse market for insulin therapies.

Download Free Sample Report

Key Market Challenges

Quality and Safety

Ensuring that human insulin products comply with national and international regulations and quality standards is an ongoing challenge. Regulatory authorities, such as the Saudi Food and Drug Authority (SFDA), play a crucial role in monitoring and enforcing these standards. Counterfeit or substandard insulin products can pose significant safety risks to patients. Regulators, manufacturers, and distributors need to work together to combat counterfeit insulin and protect patients. Proper storage and handling of insulin products are essential to maintaining their quality and safety. Variations in temperature and mishandling can compromise the effectiveness of insulin, potentially endangering patients' lives. The insulin supply chain from manufacturing to patient use is complex and includes multiple stakeholders. Ensuring the integrity of the supply chain is vital to prevent contamination or tampering with insulin products. Occasionally, insulin products may need to be recalled due to quality or safety issues. Managing these recalls and preventing patient harm is a challenge. Manufacturers must maintain strict quality control processes throughout the production of insulin. This includes testing the purity and potency of the insulin to ensure that it meets the required standards. Monitoring and reporting adverse events associated with insulin use are essential for identifying safety concerns and taking corrective actions.

Market Competition

Intense competition among pharmaceutical companies can lead to price pressure. While this can make insulin more affordable for patients, it may also affect the profitability of insulin manufacturers, potentially impacting research, and development efforts. To remain competitive, some manufacturers may cut costs, potentially compromising the quality and safety of insulin products. Regulatory authorities must ensure that all insulin products meet stringent quality standards. Gaining and maintaining market share is challenging. Established insulin manufacturers may face competition from newer entrants or biosimilar products. This competition can impact their market share and profitability. Competition encourages companies to innovate and develop new insulin products. However, keeping up with the latest technological advancements and staying ahead of competitors can be a significant challenge for manufacturers. Entering the insulin market is not easy. Manufacturers must meet regulatory requirements, ensure product quality, and invest in research and development. These barriers can be challenging for new entrants. Competition can intensify in the distribution of insulin products. Ensuring equitable access to insulin across the country, including remote areas, is a challenge for both manufacturers and distributors.

Key Market Trends

Biopharmaceutical Developments

Biopharmaceutical companies are increasingly focused on developing insulin products using biotechnological methods. These products, often referred to as recombinant human insulin or insulin analogs, are produced through genetic engineering techniques using bacteria, yeast, or mammalian cells. This results in insulin that closely mimics the structure and function of human insulin. Biotechnologically derived insulin products tend to have higher purity and potency compared to insulin extracted from animal sources. This can result in improved glycemic control and reduced risk of adverse reactions. Advances in biotechnology have enabled the development of customized insulin analogs that can better match individual patient needs. These analogs offer more flexible treatment options, allowing healthcare providers to tailor insulin therapy to specific patient profiles. Biopharmaceutical developments have led to the creation of long-acting and ultra-long-acting insulin analogs, such as insulin glargine and insulin degludec. These insulins provide a basal level of insulin action for extended periods, reducing the need for multiple daily injections. Rapid-acting insulin analogs, such as insulin lispro and insulin aspart, offer faster onset and shorter duration of action, allowing for better post-meal blood sugar control. The development of biosimilar insulins, which are highly like existing insulin products, provides more affordable alternatives for patients while maintaining comparable safety and efficacy.

Segmental Insights

Indication Insights

Based on Indication, Type Il Diabetes segment emerged as the fastest growing in the Saudi Arabia Human Insulin Market and is predicted to continue expanding over the coming years. Type II diabetes is more common than Type I diabetes, both globally and in Saudi Arabia. In Type II diabetes, the body either does not produce enough insulin or is unable to use it effectively. The higher prevalence of Type II diabetes naturally leads to a larger market share for insulin used to manage this condition. Type II diabetes is often associated with factors such as obesity, sedentary lifestyles, and poor dietary habits. Saudi Arabia, like many countries, has seen an increase in these risk factors, contributing to the rising prevalence of Type II diabetes. As populations age, the risk of developing Type II diabetes increases. Saudi Arabia, like other countries, has experienced a demographic shift with a growing elderly population, which is more prone to Type II diabetes. There is a growing emphasis on screening and early detection of Type II diabetes, leading to more people being diagnosed with this form of diabetes. Early detection often results in the initiation of insulin therapy, contributing to the demand for human insulin products. In many cases, individuals with Type II diabetes initially manage their condition with oral medications. However, as the disease progresses, some patients may require insulin therapy in combination with oral drugs. This transition to insulin treatment can boost the demand for human insulin in the Type II diabetes segment.

Onset Time Insights

Based on Onset Time, Intermediate Acting segment dominated the Saudi Arabia Human Insulin Market and is predicted to continue expanding over the coming years. Intermediate-acting insulins, such as NPH (Neutral Protamine Hagedorn) insulin, have a slower onset of action and a more extended duration compared to rapid-acting insulins. This makes them suitable for providing a basal level of insulin to manage blood glucose levels consistently over an extended period. Intermediate-acting insulins are often used as basal insulin in various insulin regimens. Basal insulin is crucial for maintaining blood sugar levels between meals and during sleep. Many patients with diabetes, particularly those with Type 1 and Type 2 diabetes, require a basal insulin component in their treatment plans. Intermediate-acting insulins are typically more cost-effective compared to newer long-acting insulin analogy, which can be important for healthcare systems and patients looking for affordable treatment options. Intermediate-acting insulins have been available for many years and are widely accessible in the Saudi Arabia market. Their availability and familiarity to healthcare providers and patients contribute to their popularity. The less frequent dosing requirement of intermediate-acting insulins, typically twice daily, can improve patient compliance compared to insulins that need more frequent injections.

Products Insights

Based on product, Insulin Pens segment dominated the Saudi Arabia Human Insulin Market in the forecast period and is predicted to continue expanding over the coming years. Insulin pens are user-friendly and offer a convenient way for patients to self-administer insulin. They are particularly favoured by patients who may have difficulty with traditional insulin vials and syringes, making them a preferred choice for many people with diabetes. Insulin pens offer more precise dosing, with clearly marked dose settings, which can be important in managing diabetes effectively. This precision can lead to improved diabetes control and better patient outcomes. Insulin pens typically use smaller, finer needles, which can result in less pain and discomfort during injections. This can improve patient compliance and overall satisfaction with insulin therapy. Insulin pens are compact and easy to carry, making them ideal for individuals who need to administer insulin while on the go. This portability and convenience are especially valuable for those with busy lifestyles. Insulin pens can be less stigmatizing compared to traditional syringes, as they look more like every day writing instruments. This can help reduce the social barriers and hesitations associated with insulin therapy.

Download Free Sample Report

Regional Insights

Based on region, Northern & Central region emerged as the largest in the Saudi Arabia Human Insulin Market in 2024. These regions are more densely populated compared to other parts of the country. A higher population generally leads to increased demand for healthcare services, including diabetes care and insulin products. Northern and Central regions often have more developed healthcare infrastructure, including hospitals, clinics, and specialized diabetes care centers. This infrastructure facilitates better access to healthcare services and diabetes management, leading to a higher demand for insulin. Urban areas in these regions tend to have a higher prevalence of diabetes due to factors such as sedentary lifestyles and dietary choices. Urban populations are more likely to require insulin for diabetes management. Economic activities, including trade, commerce, and industry, are often concentrated in these regions. This can lead to a higher incidence of diabetes due to factors such as increased stress and lifestyle changes associated with urban living. These regions often have better access to healthcare education and awareness programs, which can lead to earlier diagnosis and treatment of diabetes. This, in turn, drives the demand for insulin.

Recent Developments

• In February 2025, Sudair Pharma Company, based in Saudi Arabia, is poised to inaugurate a new insulin manufacturing facility in Sudair City for Industry and Businesses. Once operational, the plant is projected to produce over 15 million insulin pens annually, meeting the needs of 500,000 patients in its first year. This initiative is part of Sudair Pharma’s broader strategy to localize insulin production, ensuring a secure, uninterrupted supply of this essential medication and significantly reducing the Kingdom's dependence on external imports particularly crucial in light of global supply chain disruptions.
• In February 2025, Saudi Arabia has officially launched its first domestically-operated insulin manufacturing facility a pivotal advancement aligned with the objectives of Vision 2030. This development marks a significant step in localizing critical healthcare production, reducing reliance on imports, and ensuring a more resilient, self-sufficient supply chain for diabetes management across the Kingdom.
• In October 2024, Lifera, through its subsidiary SaudiBio, has entered into a strategic agreement with Novo Nordisk, the world’s leading insulin manufacturer, to localize insulin production within Saudi Arabia. This partnership not only enables the transfer of advanced biomanufacturing technology but also aims to develop a highly skilled local workforce specialized in aseptic production processes. By 2027, Saudi Arabia is positioned to become the first GCC nation to manufacture an innovator biologic insulin, marking a major milestone in regional pharmaceutical leadership and industrial capability.

Key Market Players

• Novo Nordisk Saudi Arabia
• Sanofi Saudi Arabia
• Baxter International Saudi Arabia
• B Braun Saudi Arabia
• Eli Lilly, and Company Saudi Arabia
• Pfizer Saudi Arabia

Report Scope:

In this report, the Saudi Arabia Human Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Saudi Arabia Human Insulin Market, By Indication:

o   Type I Diabetes

o   Type II Diabetes

• Saudi Arabia Human Insulin Market, By Route of Administration:

o   Subcutaneous

o   Nasal

o   Intravenous

o   Transdermal

o   Oral

o   Others

• Saudi Arabia Human Insulin Market, By Type:

o   Basal

o   Bolus

o   Pre-mixed

o   Biosimilar

o   Traditional

• Saudi Arabia Human Insulin Market, By Onset Time:

o   Rapid Acting

o   Short-Acting

o   Intermediate Acting

o   Long Acting

o   Ultra-long Acting

o   Pre-Mixed

o   Inhaled

• Saudi Arabia Human Insulin Market, By Products:

o   Insulin Pens

o   Insulin Pumps

o   Infusion System

o   Injection

• Saudi Arabia Human Insulin Market, By Region:

o   Eastern

o   Western

o   Northern & Central

o   Southern

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Saudi Arabia Human Insulin Market.

Available Customizations:

Saudi Arabia Human Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Saudi Arabia Human Insulin Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com